TLR2 TLR9 Modulators for Inflammatory Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory diseases and neurological disorders related to inflammatory signaling processes, such as those involving misfolded proteins, lack effective inhibitors that specifically target Toll-like receptors (TLR) without interfering with bacterial or viral infections.
Innovation Solution
Development of compounds that act as potent and selective antagonists or inhibitors of TLR2 and/or TLR9, designed to interfere with the heterodimerization process of TLR2 and modulate inflammatory responses, thereby treating associated diseases without affecting normal immune responses to microbial ligands.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If broad-spectrum TLR inhibitors are used to reduce inflammatory responses, then inflammatory diseases are treated, but immune response to bacterial or viral infections is compromised
Solution Approach 1:
The patent segments the TLR signaling pathway by developing compounds that specifically inhibit TLR2 or TLR9 while leaving other TLRs functional. This is achieved through selective molecular design that targets specific receptor structures, allowing treatment of inflammatory diseases without compromising immune response to bacterial or viral infections that activate other TLRs
Solution Approach 2:
The patent applies local quality by creating compounds with specific molecular characteristics that confer selectivity for TLR2 or TLR9. The compounds possess particular structural features (such as specific functional groups, ring structures, or stereochemical configurations) that enable them to bind selectively to their target receptors while avoiding off-target effects on other TLRs
2Object-affected harmful factors
If TLR2 heterodimerization is inhibited to treat neurodegenerative diseases, then inflammatory responses to misfolded proteins are reduced, but discrimination between pathological and microbial ligands is affected
Solution Approach 1:
The patent applies dynamics by developing reversible inhibitors that can dynamically regulate TLR2 heterodimerization. The compounds allow controlled modulation of the heterodimerization equilibrium, enabling inhibition of pathological ligand-induced signaling while preserving the ability to respond to microbial ligands under different conditions
Solution Approach 2:
The patent uses parameter changes by optimizing specific molecular parameters of the inhibitor compounds, such as binding affinity, selectivity ratios, and pharmacokinetic properties. These parameter optimizations enable the compounds to selectively interfere with pathological ligand binding or heterodimerization while maintaining responsiveness to microbial ligands
Data Source
AI summary
The present disclosure relates to compounds, pharmaceutical compositions comprising such compounds, and use of such compounds in methods of treatment or in medicaments for treatment of inflammatory diseases and certain neurological disorders that are related to inflammatory signaling processes, including but not limited to misfolded proteins.